Midas Pharma GmbH
Midas Pharma GmbH, a prominent player in the pharmaceutical industry, is headquartered in Germany and operates extensively across Europe and beyond. Founded in 1994, the company has established itself as a trusted partner in the development and distribution of innovative healthcare solutions. Midas Pharma focuses on contract development and manufacturing, offering a diverse range of services that include drug formulation, regulatory support, and supply chain management. Their commitment to quality and customer-centric approach sets them apart in a competitive market. With a strong emphasis on research and development, Midas Pharma has achieved significant milestones, positioning itself as a leader in the pharmaceutical sector. The company’s dedication to excellence is reflected in its robust portfolio of products and services, catering to the evolving needs of the healthcare landscape.
DitchCarbon Score
How does Midas Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Midas Pharma GmbH's score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Midas Pharma GmbH's reported carbon emissions
In 2024, Midas Pharma GmbH reported total carbon emissions of approximately 249,000 kg CO2e for Scope 1 and 16,000 kg CO2e for Scope 2 globally. Notably, their Scope 3 emissions were significantly higher, amounting to about 679,714,000 kg CO2e, with the largest contributions from purchased goods and services (approximately 678,587,000 kg CO2e) and business travel (about 776,000 kg CO2e). For the German operations in 2024, Midas Pharma GmbH disclosed Scope 1 emissions of approximately 230,000 kg CO2e. In the previous year, 2023, the global emissions were reported as 217,000 kg CO2e for Scope 1 and 16,000 kg CO2e for Scope 2, while German operations recorded Scope 1 emissions of about 201,000 kg CO2e. Despite these figures, Midas Pharma GmbH has not established specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company does not appear to inherit emissions data from a parent organization, indicating that all reported figures are self-contained within Midas Pharma GmbH. Overall, while Midas Pharma GmbH has made strides in emissions reporting, the lack of defined reduction strategies highlights an area for potential improvement in their climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 217,000 | 000,000 |
| Scope 2 | 16,000 | 00,000 |
| Scope 3 | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Midas Pharma GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
